Suppr超能文献

扩容剂休克疗法的新进展(作者译)

[New aspects of shock therapy with volume expanders (author's transl)].

作者信息

Landauer B, Krämer G

出版信息

MMW Munch Med Wochenschr. 1976 Apr 30;118(18):553-8.

PMID:58374
Abstract

For successful primary treatment of hemorrhagic shock the infusion of volume expanders is a ""conditio sine qua non''. Of the original possibilities for selection, Ringer's lactated injection can no longer be recommended for the compensation of intravascular loss in the light of more recent pathophysiological knowledge. Opposite to this, gelatin, dextran, hydroxyethyl starch, and albumin solutions are available as the mainstay of an adequate volume expansion. The danger of anaphylactoid side effects is to be estimated as about equal in all 4 groups of substances. Seen from the point of view of replacement function and of rheological and pharmacological properties, the higher molecular dextrans may still be considered the method of choice for shock therapy.

摘要

对于失血性休克的成功初始治疗,输注容量扩充剂是“必不可少的条件”。根据最新的病理生理学知识,就最初可供选择的药物而言,乳酸林格注射液已不再推荐用于补偿血管内液体丢失。与此相反,明胶、右旋糖酐、羟乙基淀粉和白蛋白溶液是充分扩容的主要药物。这四类物质发生类过敏副作用的风险大致相当。从替代功能以及流变学和药理学特性的角度来看,高分子右旋糖酐仍可被视为休克治疗的首选方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验